HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
07. Dezember 2022 07:30 ET | HCW Biologics, Inc
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical...